Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
33%
Ph not_applicable
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting3100%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome

NCT07388810
not_yet_recruitingphase_1

Ripertamab for the Treatment of Myasthenia Gravis

NCT07372807
not_yet_recruitingphase_3

Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

NCT06858722

Clinical Trials (3)

Showing 3 of 3 trials
NCT07388810Not Applicable

Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome

Not Yet Recruiting
NCT07372807Phase 1

Ripertamab for the Treatment of Myasthenia Gravis

Not Yet Recruiting
NCT06858722Phase 3

Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3